Comparative Pharmacology
Head-to-head clinical analysis: PROPHENE 65 versus PROPOXYPHENE HYDROCHLORIDE 65.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROPHENE 65 versus PROPOXYPHENE HYDROCHLORIDE 65.
PROPHENE 65 vs PROPOXYPHENE HYDROCHLORIDE 65
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Propoxyphene is a weak opioid agonist that binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering perception of pain. It also has local anesthetic and moderate antitussive effects.
Propoxyphene is a centrally acting opioid agonist that binds to mu-opioid receptors in the central nervous system, inhibiting pain signal transmission and altering pain perception. It also has local anesthetic effects.
Propoxyphene napsylate 100 mg orally every 4 hours as needed for pain; maximum 600 mg/day.
65 mg orally every 4 hours as needed for pain; maximum 390 mg/day.
None Documented
None Documented
Terminal elimination half-life of propoxyphene: 6-12 hours (mean ~8 hours); norpropoxyphene half-life: 22-36 hours, leading to accumulation with chronic dosing. Clinical context: prolonged half-life in elderly and hepatic impairment increases risk of toxicity.
6-12 hours (mean ~8 hours); prolonged in hepatic impairment and elderly; accumulation possible with repeated dosing.
Renal elimination of unchanged drug and metabolites: propoxyphene and its major metabolite norpropoxyphene account for ~20-30% as unchanged drug in urine; remainder as conjugated metabolites. Biliary/fecal elimination accounts for <10%.
Renal excretion of unchanged drug (approximately 20-30%) and metabolites; approximately 40-60% as conjugated metabolites; minor biliary/fecal elimination.
Category C
Category C
Opioid Analgesic
Opioid Analgesic